Clinical Trials Logo

Filter by:
NCT ID: NCT06442943 Recruiting - Clinical trials for Cognitive Dysfunction

Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia

Start date: June 4, 2024
Phase: N/A
Study type: Interventional

Dementia is a chronic, progressive neurodegenerative disease characterized by acquired cognitive impairment as its core manifestation. The most common type of dementia is Alzheimer's Disease (AD), also known as "Senile Dementia," accounting for 60-80% of all dementia cases. Currently, there are approximately 10 million AD patients in China, with the number showing an increasing trend year by year, imposing a heavy economic and caregiving burden on families and society. Studies have shown that AD has a clinically silent period of 15 to 20 years (SCD\MCI), where the risk of developing dementia is ten times higher than that of healthy elderly individuals. Nearly 50% of MCI patients progress to dementia within 5 years, and about 14.1% of SCD patients develop dementia within the same timeframe. Early detection, diagnosis, and intervention are currently the most effective strategies for preventing and treating AD. Therefore, this study aims to verify the intervention effect of integrated cognitive intervention in high-risk populations for senile dementia (SCD, MCI) based on the cognitive rehabilitation model through randomized controlled trials, and to analyze attrition rates, participation rates, etc., which have good research and application value.

NCT ID: NCT06442852 Recruiting - Alzheimer Disease Clinical Trials

Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

Start date: April 3, 2021
Phase:
Study type: Observational

Alzheimer's Disease, AD is a type of neurofibrillary tangles formed by the deposition of beta amyloid proteins within the nervous system cells and excessive phosphorylation of extracellular Tau proteins, NFTs are the main pathological features of central nervous system degeneration, also known as senile dementia. In addition, synaptic plasticity damage and neuroinflammation also play important roles in the progression of AD. Neurosynapses are the sites where neurons interact with each other in terms of function, and are also crucial for neuronal information transmission and communication. Synapses are the fundamental units in the brain, and synaptic activity can stimulate the maturation of mushroom like dendritic spines and form new synapses, enabling synaptic strength to adapt to changes in the internal and external environment, thereby playing an important role in learning and memory. Previous studies have shown that synaptic activity interruption and synaptic loss can already be detected in the AD brain, especially in the early stages. Multiple studies have shown a higher correlation between synaptic disorders characterized by synaptic loss and decreased synaptic activity and cognitive impairment in Alzheimer's disease compared to age-related plaques and neurofibrillary tangles. Therefore, understanding the potential mechanisms of synaptic disorders will contribute to the development of early treatment strategies for AD. MicroRNAs (miRNAs) are a type of small non coding RNA with a length of approximately 22 nucleotides. Their main function is to silence target genes at the post transcriptional level and inhibit the translation process of their proteins. MiRNAs are involved in many physiological processes and pathological pathways, including development, tumorigenesis, and heart disease. Recently, people have also studied the abnormal regulatory role of miRNAs in AD synaptic disorders. Some miRNAs enriched in the brain, such as miR-124, MiR-132 is abnormally expressed in the AD brain, mediating synaptic plasticity damage. However, most of the miRNAs mentioned above are not directly related to synaptic activity, and their regulation of AD synaptic damage is likely to be a broad-spectrum effect. At present, there are 12 miRNAs closely related to synaptic plasticity that have been identified. By detecting changes in miRNAs closely related to synaptic plasticity in peripheral blood of AD patients and healthy volunteers, and exploring their relationship with the severity of AD lesions, it may provide new directions for early diagnosis of AD. The purpose of this study is to: (1) detect the expression levels of miRNAs closely related to synaptic plasticity in the peripheral blood of healthy volunteers and AD patients, and identify the miRNAs with the greatest differences; (2) Analyze the relationship between the expression levels of the aforementioned miRNAs in the peripheral blood of AD patients and the severity of the disease; (3) Analyze the relationship between the expression levels of the aforementioned miRNAs in the peripheral blood of AD patients and the commonly used neuropsychiatric scale scores. We plan to clarify the changes in peripheral blood miRNAs and their relationship with the severity of AD through case-control studies, in order to provide new directions for early diagnosis of AD.

NCT ID: NCT06442839 Recruiting - Clinical trials for Develop a CT-based Tumor Budding Predictive Model for Bladder Cancer Using Deep Learning Algorithms

AI-Based Imaging Model for Bladder Cancer Prediction

Start date: May 1, 2024
Phase:
Study type: Observational

Bladder cancer is the ninth most common malignant tumor worldwide, characterized by high malignancy and poor prognosis. We intend to develop a CT-based tumor budding predictive model for bladder cancer using deep learning algorithms. This model will facilitate preoperative assessment of patient conditions, enabling the formulation of more precise and personalized treatment plans.

NCT ID: NCT06441669 Recruiting - Clinical trials for Cytomegalovirus Infection Reactivation

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Start date: May 1, 2024
Phase:
Study type: Observational

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

NCT ID: NCT06441565 Recruiting - Colorectal Cancer Clinical Trials

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Start date: May 24, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.

NCT ID: NCT06441513 Recruiting - Cancer Clinical Trials

The Preventive Effect of Chemotherapy-induced Hand-foot Syndrome

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

this study will use traditional Chinese medicine bath with no obvious side effects combined with case tracking management mode to form nursing measures to prevent hand foot syndrome. A randomized controlled trial design will be used to collect cases of hand foot syndrome (HFS) that did not appear after chemotherapy in the ward of the Department of chemotherapy, Peking University Third Hospital, and carry out nursing intervention.

NCT ID: NCT06441357 Recruiting - Clinical trials for Adenocarcinoma of Lung

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Start date: June 1, 2024
Phase:
Study type: Observational

The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.

NCT ID: NCT06441227 Recruiting - Clinical trials for Lipoprotein Disorder Disease

Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

Start date: June 13, 2024
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-5346 in healthy subjects, and to evaluate the food effects on PK of HRS-5346.

NCT ID: NCT06441110 Recruiting - Clinical trials for Urinary Bladder Neoplasms

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer. However, research on the combination of tislelizumab and BCG for bladder cancer treatment has largely been retrospective. Currently, ongoing clinical trials have not discussed the effectiveness of PD-1/PD-L1 inhibitors combined with BCG instillation in reducing postoperative recurrence in intermediate-risk NMIBC. Therefore, this study aims to explore the clinical efficacy and safety of tislelizumab combined with BCG in the treatment of intermediate and high-risk NMIBC. For this purpose, investigators have established strict screening criteria to include eligible patients in the study and have recruited suitable patients from multiple medical centers.Investigators have also developed a meticulous implementation process and follow-up considerations, hoping to better verify the clinical efficacy and safety of the combined use of these two drugs.

NCT ID: NCT06440954 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

EPIC
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.